智通财经APP获悉，Deciphera Pharmaceuticals(DCPH.US)周一宣布，日本小野药品工业(OPHLY.US)已同意以24亿美元的总股本价值收购这家癌症药物开发商。受此消息提振，截至发稿，Deciphera 盘前大涨71%。 据悉，小野药品工业将通过要约收购方式，以每股25.60美元价格现金收购 ...

Deciphera Pharmaceuticals今日宣布，已与ONO Pharmaceutical达成确定性的合并协议。根据该协议，ONO将斥资约24亿美元收购Deciphera。通过此次合并，ONO和Deciphera将加速实现它们的共同愿景，向全球患者提供创新药物。 Deciphera拥有激酶药物发现和开发的专长，以及在美国和 ...

The trial is enrolling in the US and will include regions in the Asia Pacific, Europe, Latin America, and North America.

Deciphera Pharmaceuticals(DCPH.US)周一宣布，日本小野药品工业(OPHLY.US)已同意以24亿美元的总股本价值收购这家癌症药物开发商。受此消息提振，截至发稿，Deciphera 盘前大涨71%。 据悉，小野药品工业将通过要约收购方式，以每股25.60美元价格现金收购Deciphera普通股的 ...

Ono Pharmaceutical has agreed to buy cancer drugmaker Deciphera Pharmaceuticals in a deal that values the latter company at $2.4 billion. \r Per deal terms, Ono is purchasing in cash all outstanding ...

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, a clinical-stage biotechnology company focused on developing advanced kinase inhibitor treatments targeting the tumor cell and the tumor ...

Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) has recently experienced a daily loss of 2.19% and a 3-month loss of 10.22%. The company's Earnings Per Share (EPS) (EPS) also indicate a loss of 2.32.

WALTHAM, Mass.-- (BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today ...

Deciphera Pharmaceuticals, Inc. DCPH announced that it has dosed the first patient in a phase I study which is evaluating its investigational ULK kinase inhibitor, DCC-3116, for the treatment of ...

The company reported $42.1 million in revenue for 2020, up from $25 million in 2019. Qinlock (ripretinib) was responsible for most of that revenue, including $38 million in the U.S. and $1.5 million ...